Genmab AS Aktie - GE9

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

180,75

Gebot

179,75

Fragen

181,70

Volumen

179,10 Tagesbereich 181,65

155,00 52-Wochen-Bereich 278,50

Marktkapitalisierung

11,874B

Handelsende

180,25

Handelsbeginn

181,05

Letzte Trade

180.55

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

512

Ausgegebene Aktien

65.691.573

Dividendenrendite

Kurs-Gewinn-Verhältnis

1,51

Gewinn pro Aktie (EPS)

119,41

Erlöse

21,53B

Nettogewinn

7,84B

Sektor

Biological Pds,ex Diagnstics

Branche

Biogenetic (human)

Website

www.genmab.com

Hauptsitz

Copenhagen, Dnk

Gegründet

2000

Genmab AS is listed in the Biological Pds,ex Diagnstics sector of the Tradegate (DE) with ticker GE9. The last closing price for Genmab AS was 180,25 €. Over the last year, Genmab AS shares have traded in a share price range of 155,00 € to 278,50 €.

Genmab AS currently has 65.691.573 shares in issue. The market capitalisation of Genmab AS is 11,84 € billion. Genmab AS has a price to earnings ratio (PE ratio) of 1.51.

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; April 22, 2025 – Genmab A/S (Nasdaq: GMAB). On...

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025 Company Announcement Net sales of DARZALEX® in the first quarter...

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; April 14, 2025 – Genmab A/S (Nasdaq: GMAB). On...

Genmab A/S Share Capital Reduction

Genmab A/S Share Capital Reduction Company Announcement COPENHAGEN, Denmark; April 10, 2025 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S’ Annual...

Transactions In Connection with Share Buy-back Program

Transactions In Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; April 7, 2025 – Genmab A/S (Nasdaq: GMAB). On...

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons Company...

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer Media Release...

Transactions in connection with share buy-back program

Transactions in connection with share buy-back program Company Announcement COPENHAGEN, Denmark; March 31, 2025 – Genmab A/S (Nasdaq: GMAB). On...

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer...

Genmab Announces Initiation of Share Buy-Back Program

Genmab Announces Initiation of Share Buy-Back Program Company Announcement Repurchase of up to 2.2 million shares with a maximum aggregate total...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	6.45	3.70051635112	174.3	181.65	171.8	333	175.66978958	DE
4	-6.45	-3.44551282051	187.2	187.2	155	362	170.83944671	DE
12	-10.7	-5.58892661269	191.45	223.8	155	512	191.08377073	DE
26	-31.85	-14.9811853246	212.6	223.8	155	463	196.39122843	DE
52	-85.45	-32.0999248685	266.2	278.5	155	338	210.61516276	DE
156	-178.85	-49.7358175751	359.6	362.9	155	262	225.71356496	DE
260	-192.85	-51.619379015	373.6	374.3	155	221	226.27804195	DE

GE9 - Frequently Asked Questions (FAQ)

What is the current Genmab AS share price?

The current share price of Genmab AS is 180,75 €

How many Genmab AS shares are in issue?

Genmab AS has 65.691.573 shares in issue

What is the market cap of Genmab AS?

The market capitalisation of Genmab AS is EUR 11,84B

What is the 1 year trading range for Genmab AS share price?

Genmab AS has traded in the range of 155,00 € to 278,50 € during the past year

What is the PE ratio of Genmab AS?

The price to earnings ratio of Genmab AS is 1,51

What is the cash to sales ratio of Genmab AS?

The cash to sales ratio of Genmab AS is 0,55

What is the reporting currency for Genmab AS?

Genmab AS reports financial results in DKK

What is the latest annual turnover for Genmab AS?

The latest annual turnover of Genmab AS is DKK 21,53B

What is the latest annual profit for Genmab AS?

The latest annual profit of Genmab AS is DKK 7,84B

What is the registered address of Genmab AS?

The registered address for Genmab AS is KALVEBOD BRYGGE 43, COPENHAGEN, 1260

What is the Genmab AS website address?

The website address for Genmab AS is www.genmab.com

Which industry sector does Genmab AS operate in?

Genmab AS operates in the BIOGENETIC (HUMAN) sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
WW6Ww International Inc	0,3468 € (169,88%)	144,1k
OYM1Odyssey Marine Exploration Inc	1,39 € (82,89%)	120,38k
VW5Cannabist Company Holdings Inc	0,0643 € (78,61%)	153,41k
Z620Trillion Energy International Inc	0,0307 € (48,31%)	103,45k
K8DWellfield Technologies Inc	0,0142 € (47,92%)	500
A07Avance Gas Holding Ltd	0,27 € (-46,80%)	1,26M
3SHShunfeng International Clean Energy Limited	0,0014 € (-36,36%)	3k
SQRSaia Inc.	216,00 € (-30,77%)	528
L7C2Windfall Geotek Inc	0,008 € (-30,43%)	32,29k
3PJ1Golden Dory Resourses	0,02 € (-25,93%)	40k
DMLSayona Mining Limited	0,0113 € (4,63%)	2,52M
11LCanopy Growth Corporation	1,222 € (-6,86%)	2,31M
PF8European Lithium Limited	0,0314 € (3,29%)	2,18M
D7GNel ASA	0,1982 € (-1,49%)	2,15M
3CPXiaomi Corporation	5,459 € (-1,83%)	1,56M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Genmab AS (GE9)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Genmab AS

GE9 Neueste Nachrichten

Transactions in Connection with Share Buy-back Program

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Transactions in Connection with Share Buy-back Program

Genmab A/S Share Capital Reduction

Transactions In Connection with Share Buy-back Program

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Transactions in connection with share buy-back program

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Genmab Announces Initiation of Share Buy-Back Program

GE9 - Frequently Asked Questions (FAQ)

Beweger

GE9 Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Genmab AS (GE9) Börsenkurse

Genmab AS (GE9)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Genmab AS

GE9 Neueste Nachrichten

Transactions in Connection with Share Buy-back Program

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Transactions in Connection with Share Buy-back Program

Genmab A/S Share Capital Reduction

Transactions In Connection with Share Buy-back Program

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Transactions in connection with share buy-back program

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Genmab Announces Initiation of Share Buy-Back Program

GE9 - Frequently Asked Questions (FAQ)

Beweger

GE9 Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich für ein Konto unter ADVFN

Werbung entfernen